• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Experiences with doxo/epirubicin and medroxyprogesterone acetate (MPA) in prostatic cancer.

作者信息

Anderström C

机构信息

Department of Urology, Kärnsjukhuset, Skövde, Sweden.

出版信息

Cancer Chemother Pharmacol. 1994;35 Suppl:S97-100. doi: 10.1007/BF00686930.

DOI:10.1007/BF00686930
PMID:7994797
Abstract

Maximal androgen blockade (MAB) has been reported to prolong the time to progression and the duration of survival in metastatic prostatic cancer. The addition of epirubicin to MAB in such patients seems to improve the therapeutic results further. The beneficial effect of combining castration with epirubicin in metastatic cases appears questionable. In comparing the time to progression in patients treated with MAB +/- epirubicin versus castration +/- epirubicin or estramustine, many studies reveal similar figures. Whether the results after treatment are actually improved remains controversial. In hormone-refractory cases, medroxyprogesterone acetate (MPA) alone seems superior to estramustine or prednisolone treatment. Combining MPA and epirubicin improves the results, but even if the improvement is of clinical value, it is nonetheless of limited magnitude.

摘要

相似文献

1
Experiences with doxo/epirubicin and medroxyprogesterone acetate (MPA) in prostatic cancer.
Cancer Chemother Pharmacol. 1994;35 Suppl:S97-100. doi: 10.1007/BF00686930.
2
Epirubicin and medroxyprogesterone acetate versus estramustine phosphate in hormone-resistant prostatic cancer: a prospective randomized study.表柔比星与醋酸甲羟孕酮对比磷酸雌莫司汀治疗激素抵抗性前列腺癌：一项前瞻性随机研究
Eur Urol. 1995;27(4):301-5. doi: 10.1159/000475185.
3
A randomized study on hormone-resistant prostatic cancer: estramustine phosphate versus low dose epirubicin with or without medroxyprogesterone acetate. A Norwegian multicenter study.一项关于激素抵抗性前列腺癌的随机研究：磷酸雌莫司汀与低剂量表柔比星对比，联合或不联合醋酸甲羟孕酮。一项挪威多中心研究。
Scand J Urol Nephrol. 1990;24(4):243-7.
4
Effect of medroxyprogesterone acetate, alone or in combination with epirubicin hydrochloride, on the growth of the Dunning R3327H prostatic adenocarcinoma.
Eur Urol. 1987;13(3):203-6. doi: 10.1159/000472774.
5
Quality of life assessment in patients with hormone-resistant prostate cancer treated with epirubicin or with epirubicin plus medroxy progesterone acetate - is it feasible?
Eur Urol. 2000 Sep;38(3):259-64. doi: 10.1159/000020291.
6
Epirubicin plus medroxyprogesterone as second-line treatment of advanced prostatic cancer. A study by the Italian Trials in Medical Oncology Group.表柔比星加甲羟孕酮作为晚期前列腺癌的二线治疗。意大利医学肿瘤学试验组的一项研究。
Am J Clin Oncol. 1995 Jun;18(3):239-44. doi: 10.1097/00000421-199506000-00011.
7
Sequentially alternating hormone chemotherapy with high-dose medroxy-progesterone acetate and low-dose epirubicin for the treatment of hormone-resistant metastatic prostatic cancer.大剂量醋酸甲羟孕酮与小剂量表柔比星序贯交替激素化疗治疗激素抵抗性转移性前列腺癌。
Eur Urol. 1988;15(1-2):43-7. doi: 10.1159/000473393.
8
Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.晚期前列腺癌中单纯全雄激素阻断与联合每周表柔比星治疗的随机对照研究
Eur Urol. 1997;32 Suppl 3:81-5.
9
Hormone-resistant metastatic prostate cancer. Comparisons between estramustine phosphate and low-dose epirubicin treatments.激素抵抗性转移性前列腺癌。磷酸雌莫司汀与低剂量表柔比星治疗的比较。
Eur Urol. 1991;19(1):12-5.
10
Epirubicin plus flutamide and orchidectomy in previously untreated advanced prostatic cancer.表柔比星联合氟他胺及睾丸切除术治疗既往未治疗的晚期前列腺癌
Semin Oncol. 1991 Oct;18(5 Suppl 6):26-8.

本文引用的文献

1
Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center.醋酸戈舍瑞林与氟他胺对比双侧睾丸切除术：一项欧洲癌症研究与治疗组织（EORTC）的III期试验（30853）。EORTC泌尿生殖系统肿瘤研究组和EORTC数据中心。
Urology. 1993 Aug;42(2):119-29; discussion 129-30. doi: 10.1016/0090-4295(93)90634-m.
2
Epirubicin and medroxyprogesterone acetate versus estramustine phosphate in hormone-resistant prostatic cancer: a prospective randomized study.表柔比星与醋酸甲羟孕酮对比磷酸雌莫司汀治疗激素抵抗性前列腺癌：一项前瞻性随机研究
Eur Urol. 1995;27(4):301-5. doi: 10.1159/000475185.
3
Weekly doxorubicin in endocrine-refractory carcinoma of the prostate.
每周使用阿霉素治疗内分泌难治性前列腺癌。
J Clin Oncol. 1983 Aug;1(8):477-82. doi: 10.1200/JCO.1983.1.8.477.
4
Low-dose doxorubicin in the management of advanced carcinoma of the prostate.低剂量阿霉素用于晚期前列腺癌的治疗
Br J Urol. 1983 Dec;55(6):747-8. doi: 10.1111/j.1464-410x.1983.tb03418.x.
5
A randomized study of doxorubicin versus doxorubicin plus cisplatin in endocrine-unresponsive metastatic prostatic carcinoma.
Cancer. 1985 Dec 1;56(11):2580-6. doi: 10.1002/1097-0142(19851201)56:11<2580::aid-cncr2820561108>3.0.co;2-w.
6
Estramustine phosphate compared with diethylstilbestrol. A randomized, double-blind, crossover trial for stage D prostate cancer.磷酸雌莫司汀与己烯雌酚比较：D期前列腺癌的一项随机、双盲、交叉试验
Am J Clin Oncol. 1986 Aug;9(4):341-51. doi: 10.1097/00000421-198608000-00014.
7
High-dose medroxyprogesterone acetate versus prednisolone in hormone-resistant prostatic cancer. A pilot study.高剂量醋酸甲羟孕酮与泼尼松龙治疗激素抵抗性前列腺癌的对比：一项初步研究
Eur Urol. 1985;11(1):11-6. doi: 10.1159/000472441.
8
Hormonal effects of high dose medroxyprogesterone acetate treatment in males with renal or prostatic adenocarcinoma.
Scand J Urol Nephrol. 1988;22(1):15-8. doi: 10.1080/00365599.1988.11690377.
9
Effect of medroxyprogesterone acetate, alone or in combination with epirubicin hydrochloride, on the growth of the Dunning R3327H prostatic adenocarcinoma.
Eur Urol. 1987;13(3):203-6. doi: 10.1159/000472774.
10
Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group.己烯雌酚、醋酸环丙孕酮和醋酸甲羟孕酮治疗晚期前列腺癌的比较：欧洲癌症研究与治疗组织泌尿学组一项随机III期试验的最终分析
J Urol. 1986 Sep;136(3):624-31. doi: 10.1016/s0022-5347(17)44996-2.